- Vectura reports 2020 financial performance on-track
- Company demonstrates progress on strategy execution with 12 new CDMO deals signed year to date
Vectura Group plc today announces its unaudited Interim Results for the six-months ended 30 June 2020. For the full update, please click here.
Commenting on the results, Will Downie, Chief Executive Officer of Vectura, said:
“I am pleased to report that financial performance for 2020 is on-track, with our base business proving resilient in the face of wider challenges posed by the Coronavirus outbreak. We are continuing to execute on our inhalation CDMO strategy and have signed 12 new deals to date, revenue from which will begin to feed through in the second half of the year.”
“We welcomed the recent approval of Novartis’s Enerzair® Breezhaler® (QVM149) in both Europe and Japan, and VR315 (US) remains under review by the FDA with potential approval and launch in the second half of the year. Clearly there are still uncertainties related to the current pandemic situation, but with measures in place to mitigate risks, combined with a positive outlook for our inhaled CDMO business, we are confident 2020 will be another year of strong delivery for Vectura.”
Analyst webcast and conference call
Chief Executive Officer Will Downie and Chief Financial Officer Paul Fry presented the Interim Results via live webcast earlier today. The presentation slides and a recording of the briefing are available here.